Eos Biosciences Inc. is a privately held, oncology-focused, Nanomedicines company with an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed at Cedars-Sinai Medical Center (Los Angeles). The technology is based on generating self-assembling, nanobiologic particles (Eosomes) that entrap and encapsulate a chosen therapeutic and specifically deliver it to the interior of the target disease cell. Such specific targeting allows for improved efficacy and safety profiles of the therapeutic payload. The focus is the targeting of therapeutics for oncology and immuno-oncology applications.